You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
PPARγ pure antagonist with micromolar affinity in 3T3-L1 and 3T3-F442A preadipocyte cells; selective over PPARδ and PPARα. Antagonizes the ability of rosiglitazone to stimulate transcriptional activity of PPARγ. Acts as a PPARγ agonist in an ECV304 cell line. Also produces PPARγ-independent apoptosis of tumor cells via several mechanisms. Active in vivo.
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 340.42. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.94 mL||14.69 mL||29.38 mL|
|5 mM||0.59 mL||2.94 mL||5.88 mL|
|10 mM||0.29 mL||1.47 mL||2.94 mL|
|50 mM||0.06 mL||0.29 mL||0.59 mL|
References are publications that support the biological activity of the product.
Bishop-Bailey et al (2000) Bisphenol A diglycidyl ether (BADGE) is a PPARγ agonist in an ECV304 cell line. Br.J.Pharmacol. 131 651 PMID: 11030710
Cuzzocrea et al (2004) Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-γ, reduces acute inflammation. Eur.J.Pharmacol. 483 79 PMID: 14709329
Fehlberg et al (2003) Bisphenol A diglycidyl ether-induced apoptosis involves Bax/Bid-dependent mitochondrial release of apoptosis-inducing factor (AIF), cytochrome c and Smac/DIABLO. Br.J.Pharmacol. 139 495 PMID: 12788809
Wright et al (2000) A synthetic antagonist for the peroxisome proliferator-activated receptor γ inhibits adipocyte differentiation. J.Biol.Chem. 275 1873 PMID: 10636887
If you know of a relevant reference for BADGE, please let us know.
View Related Products by Product Action
Keywords: BADGE, BADGE supplier, PPARγ, PPARgamma, antagonists, Peroxisome, Proliferator-activating, Receptors, PPARs, BisphenolA, diglycidyl, ether, Bisphenol, A, 1326, Tocris Bioscience
3 Citations for BADGE
Citations are publications that use Tocris products. Selected citations for BADGE include:
Hegde et al (2015) Critical Role of Mast Cells and Peroxisome Proliferator-Activated Receptor γ in the Induction of Myeloid-Derived Suppressor Cells by Marijuana Cannabidiol In Vivo. J Immunol 194 5211 PMID: 25917103
Alharris et al (2019) Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells. Oncotarget 10 45 PMID: 30713602
Kanabus et al (2016) The pleiotropic effects of decanoic acid treatment on mitochondrial function in fibroblasts from patients with complex I deficient Leigh syndrome. J Inherit Metab Dis 39 415 PMID: 27080638
Do you know of a great paper that uses BADGE from Tocris? Please let us know.
Reviews for BADGE
There are currently no reviews for this product. Be the first to review BADGE and earn rewards!
Have you used BADGE?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.